Focus Partners Wealth Acquires 415,104 Shares of Immunic, Inc. $IMUX

Key Points

• Focus Partners Wealth increased its stake in Immunic, Inc. by 19.1%, holding approximately 2.70% of the company with a valuation of $2.82 million.
• Multiple hedge funds, including Jane Street Group and Millennium Management, significantly raised their stakes, indicating growing institutional interest in Immunic.
• Immunic's shares recently opened at $0.77, and the average analyst rating for the stock is "Buy" with a consensus price target of $8.33.

Focus Partners Wealth increased its position in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 19.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,583,457 shares of the company's stock after acquiring an additional 415,104 shares during the period. Focus Partners Wealth owned approximately 2.70% of Immunic worth $2,816,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC boosted its holdings in shares of Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after buying an additional 479,846 shares during the last quarter. Aberdeen Group plc bought a new position in Immunic during the 1st quarter worth about $1,155,000. 683 Capital Management LLC boosted its holdings in shares of Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after buying an additional 200,000 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after buying an additional 152,726 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock.

Immunic Stock Up 0.6%

Shares of IMUX stock traded up $0.01 during trading hours on Friday, reaching $0.85. The company's stock had a trading volume of 844,114 shares, compared to its average volume of 1,280,206. The company has a market capitalization of $83.36 million, a price-to-earnings ratio of -0.90 and a beta of 1.44. Immunic, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $2.08. The firm's 50 day simple moving average is $0.89 and its 200-day simple moving average is $0.93.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). Sell-side analysts predict that Immunic, Inc. will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on IMUX. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Immunic in a research note on Friday, August 8th. B. Riley reaffirmed a "buy" rating and set a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $8.33.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.